Brief: ViroMed receives patent
05/07/2017 03:10
July 5 (Reuters) - ViroMed Co Ltd 084990.KQ :
* Says it receives patent about composition for Preventing
or Treating Peripheral Artery Disease Using Hepatocyte Growth
Factor and Stromal Cell Derived Factor 1 alpha
Source text in Korean: https://goo.gl/YMQTSQ
Further company coverage: 084990.KQ
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; Reuters Messaging:
Yinglan.Ma@thomsonreuters.com@reuters.net))
Recent news on Helixmith
See all newsBrief: Helixmith Announces Topline Results From Double-Blind Placebo Controlled Multicenter Study For TADIOS Involving 100 Subjects Infected With COVID-19
Brief: Helixmith Announces 50% Enrollment In Its Clinical Trial For COVID-19, Involving Tadios
Brief: ViroMed issues 2nd series convertible bonds worth 100 bln won
Brief: ViroMed appoints CEO
Brief: ViroMed receives patent